060 Integrated Safety of Ixekizumab in Patients With Moderate-To-Severe Psoriasis: Results From a Pooled Analysis of 7 Clinical Trials

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2016.06.077
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

059 Ixekizumab Shows No Association With MACE in Patients With Moderate-To-Severe Psoriasis: An Integrated Safety Analysis of Clinical Trials

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2016English

Ixekizumab Efficacy and Safety in Moderate-To-Severe Genital Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

The Effect of Psoriatic Arthritis on Ixekizumab Clinical Outcomes in Moderate-To-Severe Psoriasis Patients: A Post Hoc Analysis

Journal of the American Academy of Dermatology
Dermatology
2018English

Pmu66 - Cost-Effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-To-Severe Psoriasis in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pharmacokinetics and Safety of Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: Results From a Phase 2 Open-Label Study

Journal of the American Academy of Dermatology
Dermatology
2020English

540 Rapid Response in PASI, sPGA, and BSA Measures for Patients With Moderate-To-Severe Plaque Psoriasis With Ixekizumab

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Pmu67 - Cost-Effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-To-Severe Psoriasis in the United Kingdom

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2004English

Efficacy and Safety of Continuous Every 2-Week Dosing of Ixekizumab Over 52 Weeks in Patients With Moderate-To-Severe Plaque Psoriasis in a Randomized Phase 3 Trial (IXORA-P)

British Journal of Dermatology
DermatologyMedicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy